IN2015DN03135A - - Google Patents
Info
- Publication number
- IN2015DN03135A IN2015DN03135A IN3135DEN2015A IN2015DN03135A IN 2015DN03135 A IN2015DN03135 A IN 2015DN03135A IN 3135DEN2015 A IN3135DEN2015 A IN 3135DEN2015A IN 2015DN03135 A IN2015DN03135 A IN 2015DN03135A
- Authority
- IN
- India
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- substituent
- solid dispersion
- acceptable polymer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261707465P | 2012-09-28 | 2012-09-28 | |
US201361782882P | 2013-03-14 | 2013-03-14 | |
US201361831811P | 2013-06-06 | 2013-06-06 | |
PCT/IB2013/003026 WO2014068402A2 (en) | 2012-09-28 | 2013-09-27 | Pharmaceutical formulation containing thienotriazolodiazepine compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN03135A true IN2015DN03135A (he) | 2015-10-02 |
Family
ID=50475880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3135DEN2015 IN2015DN03135A (he) | 2012-09-28 | 2013-09-27 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20140107107A1 (he) |
EP (1) | EP2900221B1 (he) |
JP (1) | JP2015531365A (he) |
KR (1) | KR20150100613A (he) |
CN (1) | CN104968334B (he) |
AU (1) | AU2013340483B2 (he) |
BR (1) | BR112015006537A2 (he) |
CA (1) | CA2885944A1 (he) |
HK (2) | HK1210434A1 (he) |
IN (1) | IN2015DN03135A (he) |
MX (1) | MX2015003771A (he) |
RU (1) | RU2015115634A (he) |
WO (1) | WO2014068402A2 (he) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5935030B2 (ja) | 2010-05-14 | 2016-06-15 | ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド | 白血病を治療するための組成物および方法 |
HUE031073T2 (en) | 2010-05-14 | 2017-06-28 | Dana Farber Cancer Inst Inc | Thieno triazolo-diazepine compounds for the treatment of neoplasia |
US9266891B2 (en) * | 2012-11-16 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors |
KR102355670B1 (ko) | 2013-03-15 | 2022-02-08 | 인사이트 홀딩스 코포레이션 | Bet 단백질 저해제로서의 삼환식 복소환 |
CA2917319A1 (en) | 2013-07-08 | 2015-01-15 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
CN106029077A (zh) | 2013-08-01 | 2016-10-12 | 翁科埃斯克斯有限公司 | 包含噻吩并三唑并二氮杂卓化合物的药物制剂 |
WO2015018520A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma |
WO2015018523A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A novel bet-brd inhibitor for treatment of solid tumors |
CN105899212A (zh) * | 2013-08-06 | 2016-08-24 | 翁科埃斯克斯有限公司 | 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法 |
WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
MX2016005980A (es) | 2013-11-08 | 2016-12-09 | Dana Farber Cancer Inst Inc | Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal. |
WO2015081189A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
CN105960239A (zh) * | 2013-11-27 | 2016-09-21 | 翁科埃斯克斯有限公司 | 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法 |
WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
US10793571B2 (en) | 2014-01-31 | 2020-10-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
CA2936865A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
MX2016011160A (es) | 2014-02-28 | 2017-04-27 | Tensha Therapeutics Inc | Tratamiento de afecciones asociadas con la hiperinsulinemia. |
UA119870C2 (uk) | 2014-04-23 | 2019-08-27 | Інсайт Корпорейшн | 1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET |
US9956228B2 (en) * | 2014-05-02 | 2018-05-01 | Oncoethix Gmbh | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds |
AU2015252940A1 (en) * | 2014-05-02 | 2016-11-17 | Kay NOEL | Method of treating resistant non-Hodgkin lymphoma, medulloblastoma, and/or ALK+non-small cell lung cancer using thienotriazolodiazepine compounds |
WO2015168587A1 (en) * | 2014-05-02 | 2015-11-05 | Oncoethix Sa | Method of treating resistant multiple myeloma and mantle cell lymphoma using thienotriazolodiazepine compounds |
WO2015169953A1 (en) * | 2014-05-08 | 2015-11-12 | Oncoethix Gmbh | Method of treating glioma using thienotriazolodiazepine compounds |
BR112016026046A8 (pt) | 2014-05-08 | 2021-07-20 | Oncoethix Gmbh | uso de compostos de tienotriazolodiazepina |
WO2015189814A1 (en) | 2014-06-13 | 2015-12-17 | Oncoethix Gmbh | Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds |
JP2017529332A (ja) * | 2014-08-28 | 2017-10-05 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を含む医薬組成物を用いる急性骨髄性白血病又は急性リンパ性白血病の治療方法 |
ES2855225T3 (es) | 2014-09-15 | 2021-09-23 | Incyte Corp | Heterociclos tricíclicos para su uso como inhibidores de proteínas BET |
PE20171042A1 (es) * | 2014-10-27 | 2017-07-19 | Tensha Therapeutics Inc | Inhibidores del bromodominio |
US10085979B2 (en) | 2014-12-02 | 2018-10-02 | Ignyta, Inc. | Combinations for the treatment of neuroblastoma |
WO2016176335A1 (en) | 2015-04-27 | 2016-11-03 | Concert Pharmaceuticals, Inc. | Deuterated otx-015 |
KR20180051576A (ko) | 2015-09-11 | 2018-05-16 | 다나-파버 캔서 인스티튜트 인크. | 아세트아미드 티에노트리아졸로디아제핀 및 그의 용도 |
MX2018003031A (es) | 2015-09-11 | 2018-08-01 | Dana Farber Cancer Inst Inc | Ciano tienotriazolpirazinas y usos de las mismas. |
AR106520A1 (es) | 2015-10-29 | 2018-01-24 | Incyte Corp | Forma sólida amorfa de un inhibidor de proteína bet |
SG11201803210YA (en) | 2015-11-25 | 2018-05-30 | Dana Farber Cancer Inst Inc | Bivalent bromodomain inhibitors and uses thereof |
JP7061068B2 (ja) | 2015-12-18 | 2022-04-27 | イグナイタ インコーポレイテッド | 癌治療のための併用薬 |
WO2017121806A1 (en) * | 2016-01-15 | 2017-07-20 | Sandoz Ag | Pharmaceutical composition of selexipag |
EP3192502A1 (en) * | 2016-01-15 | 2017-07-19 | Sandoz Ag | Pharmaceutical composition of selexipag |
DK3472157T3 (da) | 2016-06-20 | 2023-05-01 | Incyte Corp | Krystallinske faste former af en bet-inhibitor |
CA3069339A1 (en) | 2017-07-19 | 2019-01-24 | Ignyta, Inc. | Pharmaceutical compositions comprising entrectinib |
JP7311498B2 (ja) * | 2017-10-17 | 2023-07-19 | イグナイタ インコーポレイテッド | 薬学的組成物および剤形 |
JP2021511352A (ja) * | 2018-01-25 | 2021-05-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 急性骨髄性白血病の併用処置 |
EP4031109A1 (en) * | 2019-09-18 | 2022-07-27 | Bristol-Myers Squibb Company | Extended release dosage forms for tyk2 inhibitors |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2022034914A1 (ja) * | 2020-08-13 | 2022-02-17 | カルナバイオサイエンス株式会社 | 易溶性固形製剤およびその製法 |
CN116098870B (zh) * | 2023-04-10 | 2023-07-25 | 上海赛默罗生物科技有限公司 | α5-GABAA受体调节剂的固体分散体及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU716490B2 (en) * | 1996-09-13 | 2000-02-24 | Mitsubishi Tanabe Pharma Corporation | Thienotriazolodiazepine compounds and pharmaceutical use thereof |
JP4875277B2 (ja) * | 2000-06-16 | 2012-02-15 | 田辺三菱製薬株式会社 | 放出pH域及び/又は速度制御組成物 |
US8476260B2 (en) | 2007-12-28 | 2013-07-02 | Mitsubishi Tanabe Pharma Corporation | Antitumor agent |
BR112013022788A2 (pt) * | 2011-03-08 | 2016-12-06 | Zalicus Pharmaceuticals Ltd | "composição farmacêutica compreendendo uma dispersão sólida de 1-(4-benzidrilpiperazin-1-il)-3,3-difenilpropan-1-ona" |
-
2013
- 2013-09-27 JP JP2015533717A patent/JP2015531365A/ja not_active Ceased
- 2013-09-27 EP EP13848127.0A patent/EP2900221B1/en not_active Not-in-force
- 2013-09-27 CN CN201380061396.4A patent/CN104968334B/zh not_active Expired - Fee Related
- 2013-09-27 WO PCT/IB2013/003026 patent/WO2014068402A2/en active Application Filing
- 2013-09-27 CA CA2885944A patent/CA2885944A1/en not_active Abandoned
- 2013-09-27 BR BR112015006537A patent/BR112015006537A2/pt not_active Application Discontinuation
- 2013-09-27 MX MX2015003771A patent/MX2015003771A/es unknown
- 2013-09-27 KR KR1020157009117A patent/KR20150100613A/ko not_active Application Discontinuation
- 2013-09-27 IN IN3135DEN2015 patent/IN2015DN03135A/en unknown
- 2013-09-27 AU AU2013340483A patent/AU2013340483B2/en not_active Ceased
- 2013-09-27 RU RU2015115634A patent/RU2015115634A/ru unknown
- 2013-09-27 US US14/040,134 patent/US20140107107A1/en not_active Abandoned
-
2015
- 2015-11-17 HK HK15111309.6A patent/HK1210434A1/xx unknown
- 2015-12-04 HK HK15112002.4A patent/HK1211209A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
WO2014068402A3 (en) | 2014-10-16 |
EP2900221A2 (en) | 2015-08-05 |
HK1210434A1 (en) | 2016-04-22 |
KR20150100613A (ko) | 2015-09-02 |
CN104968334B (zh) | 2018-09-14 |
AU2013340483B2 (en) | 2018-01-18 |
CN104968334A (zh) | 2015-10-07 |
CA2885944A1 (en) | 2014-05-08 |
BR112015006537A2 (pt) | 2017-07-04 |
JP2015531365A (ja) | 2015-11-02 |
MX2015003771A (es) | 2016-03-04 |
AU2013340483A1 (en) | 2015-04-23 |
HK1211209A1 (en) | 2016-05-20 |
RU2015115634A (ru) | 2016-11-20 |
WO2014068402A2 (en) | 2014-05-08 |
US20140107107A1 (en) | 2014-04-17 |
EP2900221B1 (en) | 2019-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN03135A (he) | ||
PH12015502232A1 (en) | Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists | |
TN2015000175A1 (en) | Heteroaryl substituted pyridyl compounds useful as kinase modulators | |
PH12015501328A1 (en) | Meglumine salt of 6-flouro-3-hydroxy-2-pyrazine carboxamide | |
MX2014001879A (es) | Aminoquinazolinas como inhibidores de quinasa. | |
PH12015500345A1 (en) | Amino-quinolines as kinase inhibitors | |
IN2015DN01035A (he) | ||
EP2566477A4 (en) | AMINO-QUINOLINES AS KINASE INHIBITORS | |
MX2016007861A (es) | Compuestos de ácido dimetilbenzoico. | |
JO3318B1 (ar) | مثبطات bace | |
MX2013006034A (es) | Compuestos capaces de liberar compuestos fragantes. | |
UA116801C2 (uk) | ПОХІДНІ ПІРОЛО[2,3-d]ПІРИМІДИНУ ЯК АГОНІСТИ РЕЦЕПТОРА CB2 | |
MX2012008141A (es) | Compuestos y metodos. | |
PH12015500009A1 (en) | Phenoxyethyl piperidine compounds | |
EA201200891A1 (ru) | Производные 3,4,4a,10d-тетрагидро-1h-тиопирано[4,3-c]изохинолина | |
GB201101517D0 (en) | Receptor antagonists | |
PH12017500119A1 (en) | Phenyl tetrahydroisoquinoline compound substituted with heteroaryl | |
PH12015502462A1 (en) | Imidazo-triazine derivatives as pde10 inhibitors | |
MX342390B (es) | Proceso para preparar 3-haloalquilpirazoles. | |
MX358151B (es) | Derivado de sitaxentan. | |
IN2012DN02536A (he) | ||
UA98338C2 (en) | USE OF {2-N-[4-(6-METHYLBENZOTHIAZOLYL-2)PHENYL]IMINO-3-N-(2-ETHYLPHENYL)CARBOXAMIDO-8-METHYL-2H-PYRANO [3,2-c]PYRIDIN-5-YL}METHYL ACETATE AS AN AGENT WITH ANTICANDIDAL ACTIVITY | |
RS54314B1 (en) | (S) -2-AMINO-3-CYCLOHEXYLPROPANIC ACID DERIVATIVES, THEIR PRODUCTION AND USE | |
TH130493B (th) | อนุพันธ์ 3,4,4A,10B-เตตระไฮโดร-1H-ไธโอไพราโน-[4,3-c] ไอโซควิโนลิน (3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4,3-c] ISOQUINOLINE DERIVATIVES) |